A biotechnology company developing stem cell therapies to treat neurodegenerative diseases
Our proprietary technology converts mesenchymal stem cells into NurOwn®, a biological drug delivery system designed to support damaged neurons
NurOwn® cells dampen the immune system and secrete growth factors that help damaged neurons survive.
BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
March 15, 2018BrainStorm Cell Therapeutics to Present at the BIO Asia International Conference and the Wall Street Investor Forum
March 12, 2018BrainStorm Announces Formation of Scientific Advisory Board and Appoints Neuroscientist Jerold Chun, M.D., Ph.D., to Chair
March 8, 2018BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017
BrainStorm is proceeding with a randomized, double-blind, placebo-controlled multi-dose Phase 3 trial that is being conducted at multiple U.S. sites.
For more information on enrollment, contact one of the participating clinical trial sites.
Additional information can be found on clinicaltrials.gov under identifier (NCT number): NCT03280056.